source
- Novartis drops mid-stage radioligand therapy 177Lu-NeoB after weak early dataNovartis has discontinued its mid-stage radioligand therapy 177Lu-NeoB, which was being tested for breast cancer and other solid tumors. The company said early clinical data did not show enough ef…
- FDA revokes Orange B color additive and proposes to drop Citrus Red No. 2 from food approvalsThe U.S. Food and Drug Administration issued a final order that revokes the authorized use of Orange B as a food color additive. The agency also proposed revoking Citrus Red No. 2, a pigment autho…